Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2013)
24 slides from Cyclopharm's shareholder meeting presentation, May 15, 2013
Slide 1: Cyclopharm Limited Annual General Meeting
For personal use only Cyclopharm Limited Annual General Meeting 15 May 2013
Slide 2: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 3: Agenda
Agenda For personal use only Chairman’s Address Managing Director’s Review Question Time Business Close 3
Slide 4: Chairman's Address
For personal use only Chairman’s Address Vanda Gould 4
Slide 5: Managing Director's Review
For personal use only Managing Director’s Review James McBrayer 5
Slide 6: Mission & Values
Mission & Values For personal use only Strategy To be the recognised world leader in pulmonary imaging and the Australasian manufacturing leader of radiopharmaceuticals used in Positron Emission Tomography Mission Cyclopharm’s mission is to enable nuclear medicine clinicians with the ability to impr
Slide 7: Cyclopharm business
Cyclopharm business Three business units For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to
Slide 8: Highlights – 2012
Highlights – 2012 For personal use only Delivering on our Strategy Technegas business strong and consistent with Patient Administration Sets (PAS) units increasing 6% over previous year United States FDA Clinical trial commences Q4 2012 Cyclotron facility completed its second year of operation
Slide 9: 2012 Financials
For personal use only 2012 Financials 9
Slide 10: Profit & Loss
Profit & Loss For personal use only Foundation strong while investing for the future 2012 2011 Technegas Division • TG revenue consistent with Sales Revenue $9,367,984 $9,465,455 prior year with PAS volumes Profit Before Tax and Finance Costs $1,124,977 $1,699,883 6% higher Molecular Imaging • $1,7
Slide 11: Balance Sheet
Balance Sheet For personal use only Improved Net Asset Position 31‐Dec‐12 31‐Dec‐11 Current Assets $9,032,983 $8,687,324 • Net Capital Raising of Non‐current Assets $12,623,380 $12,605,889 $1.90m Total Assets $21,656,363 $21,293,213 • Increase in Inventory Current Liabilities $5,928,044 $6,575,368
Slide 12: Segmental Overview
For personal use only Segmental Overview 12
Slide 13: Technegas Global footprint
Technegas Global footprint For personal use only • Technegas is sold in 55 countries across the world • Nearly 3,000,000patient studies since 1986 • 180,000 patient studies conducted in 2012 • 1,300Technegas generators sold globally Asia Americas, • Expanding operations in North America pending 19%
Slide 14: Technegas Sales Revenue
Technegas Sales Revenue For personal use only Technegas sales volumes continue to rise Technegas Revenue in $m Patient Administration Sets (PAS) 7.35 7.27 • PAS revenue flat from 2011 • PAS volumes up 6% from 2011 1.17 1.22 2011 2012 Technegas Generators PAS TG Generators • TG Generator revenue up 4
Slide 15: Cyclopet Molecular Imaging
Cyclopet For personal use only Molecular Imaging ‐ growth despite intense competition Cyclopet • Second full year of operations recording revenue at $1,376k equating to 62% growth • Strong competition from public sector cyclotron facilities in NSW • Lag in indication approval/funding compared to the
Slide 16: Radiopharmaceuticals - Positron Emission Tomography (PET)
Radiopharmaceuticals‐ Positron Emission Tomography (PET) For personal use only PET is the future of Nuclear Medicine. Positron Emission Tomography allows physicians to differentiate between healthy and active diseased tissue. PET is primarily used in the detection of cancer but rapid growth in . oth
Slide 17: An Aging Population
An Aging Population The Healthcare Imperative For personal use only Cancer • 1 in 2 males and 1 in 3 females Australia’s Population to 2041 will be directly affected by cancer (excluding NMSC) before the > 65‐85 expected to increase by 43% age of 85 > 85 expected to increase > 300% • Cancer costs mo
Slide 18: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only PET • Joint venture with: X‐Ray • 50% Alfred Health Solutions • 30% Macquarie University CT • 20% CycloPet • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform MRI • Macquarie University Hospital start‐up slower t
Slide 19: Product Development – Ultralute
Product Development – UltraluteTM For personal use only • Cyclopharm patented technology • Concentrates Tc‐99m eluate • On‐line solution • Designed for multiple use • Extends the effective life of Mo‐99 generator up to 50% • Improves utilisation of Tc‐99m • Regulatory approval process underway 19
Slide 20: Business Outlook 2013
For personal use only Business Outlook 2013 20
Slide 21: Business Outlook
Business Outlook For personal use only Driving our Strategy Forward Continue USFDA trial targeting completion late 2014 with commercialisation in 2015 Develop additional Technegas indications to include COPD Continue to expand our PET offering through new products and locations Continue to p
Slide 22: Conclusion
For personal use only Conclusion 22
Slide 23: Question Time & Business
For personal use only Question Time & Business 23
Slide 24: Proxy Summary
Proxy Summary For personal use only Resolution Business For* Against Abstain Proxy’s discretion 1 Remuneration Report 31,551,351 35,976 23,155 5,000 2 Re-election of Mr Heaney 31,602,937 7,545 - 5,000 3 Renewal of share buy- 31,605,985 3,647 850 5,000 back capacity 4 Issue of shares under LTI 31,497